A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP) (0966-205)(TERMINATED)

• Status: Terminated
• Trial end date: 2004-10-11
• Target enrollment: 0
• Participant gender: All

Summary

A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Rofecoxib

Criteria

Inclusion Criteria:

• Males or females at least 18 years of age with familial adenomatous polyposis.